Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells.

Ball S, Li C, Li PK, Lin J.

PLoS One. 2011 Apr 19;6(4):e18820. doi: 10.1371/journal.pone.0018820.

2.

Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.

Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E, Pandit B, Ihnat MA, Shenoy SS, Kulp S, Li PK, Li C, Fuchs J, Lin J.

Cancer Res. 2010 Mar 15;70(6):2445-54. doi: 10.1158/0008-5472.CAN-09-2468. Epub 2010 Mar 9.

3.

A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.

Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, Cen L, Li C, Lin J.

Neoplasia. 2010 Jan;12(1):39-50.

4.

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, Wang L, Ye M, McEachern K, Chen H, Morosini D, Bell K, Alimzhanov M, Ioannidis S, McCoon P, Cao ZA, Yu H, Jove R, Zinda M.

Cancer Cell. 2009 Dec 8;16(6):487-97. doi: 10.1016/j.ccr.2009.10.015.

5.

Stat3 promotes directional cell migration by regulating Rac1 activity via its activator betaPIX.

Teng TS, Lin B, Manser E, Ng DC, Cao X.

J Cell Sci. 2009 Nov 15;122(Pt 22):4150-9. doi: 10.1242/jcs.057109. Epub 2009 Oct 27.

6.

Characterization of STAT3 activation and expression in canine and human osteosarcoma.

Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li PK, Kisseberth WC, London CA.

BMC Cancer. 2009 Mar 10;9:81. doi: 10.1186/1471-2407-9-81.

7.

STAT3-stathmin interactions control microtubule dynamics in migrating T-cells.

Verma NK, Dourlat J, Davies AM, Long A, Liu WQ, Garbay C, Kelleher D, Volkov Y.

J Biol Chem. 2009 May 1;284(18):12349-62. doi: 10.1074/jbc.M807761200. Epub 2009 Feb 26.

8.

The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade.

Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, Sjoberg E, Kostecke AP, Gupta S, Kumar SR, Gill PS.

Blood. 2009 Jan 1;113(1):254-63. doi: 10.1182/blood-2008-02-140020. Epub 2008 Oct 3.

9.

Molecular characterization of the pediatric preclinical testing panel.

Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC, Gilbertson R, Khan J, Smith MA, Houghton PJ.

Clin Cancer Res. 2008 Jul 15;14(14):4572-83. doi: 10.1158/1078-0432.CCR-07-5090.

10.

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.

Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA.

Pediatr Blood Cancer. 2008 Jul;51(1):42-8. doi: 10.1002/pbc.21535.

PMID:
18293383
11.

Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells.

Chen CL, Loy A, Cen L, Chan C, Hsieh FC, Cheng G, Wu B, Qualman SJ, Kunisada K, Yamauchi-Takihara K, Lin J.

BMC Cancer. 2007 Jun 28;7:111.

12.

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.

Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA.

Pediatr Blood Cancer. 2008 Mar;50(3):581-7.

PMID:
17457854
13.

STAT3: a critical transcription activator in angiogenesis.

Chen Z, Han ZC.

Med Res Rev. 2008 Mar;28(2):185-200. Review.

PMID:
17457812
14.
15.

The pediatric preclinical testing program: description of models and early testing results.

Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA.

Pediatr Blood Cancer. 2007 Dec;49(7):928-40.

PMID:
17066459
16.

STAT3 is activated in a subset of the Ewing sarcoma family of tumours.

Lai R, Navid F, Rodriguez-Galindo C, Liu T, Fuller CE, Ganti R, Dien J, Dalton J, Billups C, Khoury JD.

J Pathol. 2006 Apr;208(5):624-32.

PMID:
16463269
17.

A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells.

Song H, Wang R, Wang S, Lin J.

Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4700-5. Epub 2005 Mar 21.

18.

Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C.

Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I, Bromberg JF.

Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10602-7. Epub 2004 Jul 12.

19.

Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation.

Yahata Y, Shirakata Y, Tokumaru S, Yamasaki K, Sayama K, Hanakawa Y, Detmar M, Hashimoto K.

J Biol Chem. 2003 Oct 10;278(41):40026-31. Epub 2003 Jul 21.

20.

VEGF differentially activates STAT3 in microvascular endothelial cells.

Bartoli M, Platt D, Lemtalsi T, Gu X, Brooks SE, Marrero MB, Caldwell RB.

FASEB J. 2003 Aug;17(11):1562-4. Epub 2003 Jun 17.

Items per page

Supplemental Content

Write to the Help Desk